Will GLP-1 Transform Childhood Obesity Treatment? New Research Highlights the Importance of Nutritional Management

GLP-1 receptor agonists are significantly transforming the landscape of obesity treatment. These medications help with weight loss by suppressing appetite and enhancing the feeling of fullness, and they are increasingly being used not only for adults but also for children and adolescents.

On the other hand, new challenges are emerging.

A study published in "Childhood Obesity" in September 2026 revealed that among patients aged 10 to 17 using GLP-1 receptor agonists, about 1 in 6 were diagnosed with nutritional deficiencies or related issues within a year of starting treatment.

Vitamin D deficiency was particularly notable.

In obesity treatment, the focus often tends to be on "how much weight has been lost." However, for growing children, the important aspect is not just reducing weight. It is crucial to ensure adequate nutrition to build bones, develop muscles, produce blood, and support the overall growth of the body.

This study highlights the need to pay attention to aspects beyond just the "weight" numbers when considering GLP-1 treatment for children.

Out of 2,031 individuals studied, 16.8% were diagnosed within a year

The research team utilized extensive medical insurance claim data accumulated in the United States from 2017 to 2022.

The subjects were 2,031 users of GLP-1 receptor agonists aged 10 to 17. Patients who had not been diagnosed with nutritional deficiencies before using the medication were selected, and it was investigated whether new diagnoses related to nutritional deficiencies were recorded within the following year.

The results showed that 16.88% were diagnosed with at least one nutritional deficiency or related issue within a year of starting treatment.

The most common was vitamin D deficiency at 12.4%. Additionally, nutritional anemia was observed in 1.55%, and iron deficiency anemia in 1.44%.

The average age of the subjects was 15 years. 61.5% were female, and 62.6% had been diagnosed with obesity.

Regarding the medications used, liraglutide accounted for 78.6%, dulaglutide for 10.4%, and semaglutide for 9.1%.

This is important when considering the current situation.

Semaglutide, now widely known as a GLP-1-related drug, accounted for less than 10% in this study. Therefore, the data cannot be directly applied to all current GLP-1 drugs or the latest prescription trends.

Why is nutritional deficiency a problem?

GLP-1 receptor agonists work by suppressing appetite and maintaining a feeling of fullness.

This is a significant advantage in obesity treatment.

If strong hunger is alleviated and one can be satisfied with a smaller amount of food than before, total calorie intake may decrease, potentially leading to weight loss.

However, the issue is that "eating less" and "getting enough necessary nutrients" are different matters.

If the overall amount of food consumed decreases, the intake of not only energy but also protein, iron, calcium, and vitamins may decrease.

Particularly in GLP-1 treatment, gastrointestinal symptoms such as nausea may occur, and if the variety of foods one can eat becomes limited, nutritional balance may be further disrupted.

Nutritional management is important even for adults, but it is even more significant for children and adolescents.

Adolescence is a period of rapid growth in height, bone mass, and muscle mass.

Vitamin D and calcium play crucial roles in bone health, and iron is essential for blood production.

It is necessary to consider not only "preventing overeating" but also "how to ensure necessary nutrients in a reduced diet."

Another issue is the "lack of nutritional counseling"

What stands out in this study is not just the numbers related to nutritional deficiencies.

Only 5.8% of patients received nutritional therapy or counseling within 30 days of starting GLP-1 treatment.

Even within 90 days, it was 14.7%, and within 180 days, it was 23.3%.

In other words, more than three-quarters of the patients did not have a record of receiving nutritional counseling in the insurance claim data even six months after starting treatment.

Moreover, even those who did receive nutritional counseling took an average of 149 days for the first consultation.

This is the point that researchers are concerned about.

Instead of responding after nutritional deficiencies are discovered, it might be better to consider nutritional status and diet at the point of starting medications that could change food intake.

Rather than just regularly measuring weight after prescribing the medication, it is important to check what is being eaten, whether the amount of food has not decreased excessively, and whether necessary nutrients are being consumed.

If GLP-1 becomes more widespread in pediatric obesity treatment, such a system may become important.

It's premature to consider it a "16.8% side effect"

However, interpreting this study's results as "16.8% of children using GLP-1 become nutritionally deficient" is not accurate.

This study is an observational study investigating past insurance claim information, not a randomized controlled trial.

The main point is that there was no comparison with children in similar conditions who did not use GLP-1.

For example, vitamin D deficiency does not occur only in children using GLP-1. It is known that young people with obesity may already have deficiencies in vitamin D, iron, and other nutrients.

Therefore, this study alone cannot determine how much of the nutritional deficiencies observed were related to an increase due to GLP-1 treatment.

The research paper also states that further studies incorporating causal inference are needed to clarify the causal relationship between GLP-1 use and nutritional deficiencies.

Additionally, the data used were insurance claim data, and not all patients underwent the same tests.

Conversely, it is possible that increased visits and testing opportunities after starting treatment led to the discovery of previously unnoticed nutritional deficiencies.

Rather than concluding "the drug is the cause," a more appropriate interpretation at this stage would be that "nutritional issues are not uncommon among children receiving GLP-1 treatment, and they require careful observation."

More deficiencies among patients who received nutritional counseling?

The study also presents seemingly puzzling results.

Among patients who received nutritional counseling, 23.2% were diagnosed with nutritional deficiencies within a year, compared to 14.8% of those who did not receive counseling.

Looking at the numbers alone, one might think "nutritional counseling increases deficiencies."

However, that is not necessarily the case.

Patients whose food intake had already significantly decreased, had abnormal blood tests, or experienced rapid weight loss might have been more likely to be referred to a dietitian by their doctors.

Additionally, consulting with experts could lead to evaluations of tests and dietary habits, uncovering deficiencies that had previously been overlooked.

In other words, the relationship might be reversed, where those at higher risk of deficiency were more likely to seek counseling, rather than counseling causing the deficiency.

When interpreting numbers from observational studies, attention must be paid to such aspects.

Confusion on SNS about "whether nutrition is sufficient"

The issues surrounding GLP-1 and nutrition are not limited to research papers.

In SNS communities where GLP-1 users gather, there have been ongoing discussions about "what to eat after appetite decreases" and "whether necessary nutrients are being consumed."

One adult user posted on Reddit in September 2026, mentioning that they were pointed out to have deficiencies in vitamin D and vitamin B12 during blood tests while undergoing treatment.

The user was confused because, on one hand, they were told by healthcare providers to "manage their diet better," while on the other hand, the nutritional deficiencies were explained as possibly being due to reduced food intake.

Of course, this is an individual experience and not medical evidence supporting the research results on pediatric patients.

Nevertheless, it exemplifies how the challenge of "how to prevent nutritional deficiencies while evaluating reduced intake as a treatment effect" can be confusing for actual users.

Some people using GLP-1 experience a significant decline in interest in food itself.

For those who have struggled with "not overeating," this is a major change, but it also creates a new issue of "how to obtain necessary nutrients from a smaller amount of food."

Divided opinions on SNS regarding use in children

Opinions on the use of GLP-1 in children are also divided on SNS.

In recent discussions on Reddit, adults who struggled with severe obesity since childhood expressed that having such options available when they were children might have helped them.

Some people welcome the idea of treating obesity as a medical condition rather than simply a matter of "overeating" or "lack of willpower."

On the other hand, in discussions involving parents, there are concerns not only about the effects of the medication itself but also about how to protect children's body image and relationship with food.

Adolescence is a time when awareness of appearance changes significantly.

If the message of "needing to be thin" becomes too strong, it could affect attitudes toward food and one's body, separate from the medical benefits of weight loss.

On SNS, there are voices from parents emphasizing the importance of conveying the message of "treating for health" rather than "how to lose weight."

Additionally, in communities involving pediatricians, there are discussions about the increasing number of parents seeking GLP-1, while some regions face difficulties accessing specialized pediatric obesity treatment facilities.

These posts are not medical research and do not represent the opinions of SNS as a whole.

However, it can be read that the issues surrounding GLP-1 treatment extend beyond drug safety to broader themes such as "explaining to families," "access to specialists," "nutritional support," and "children's psychology."

It's not a binary choice between "medication or lifestyle"

Since GLP-1 gained attention, debates have arisen about whether one should not rely on medication and should instead improve through diet and exercise alone.

However, current pediatric obesity treatment does not necessarily consider medication and lifestyle as mutually exclusive choices.

The American Academy of Pediatrics positions pediatric obesity as a chronic disease with complex interactions of genetic, physiological, social, and environmental factors.

In the clinical practice guidelines published in 2023, they recommend considering pharmacotherapy as an addition to treatment for health behaviors and lifestyle for adolescents aged 12 and older with obesity, after evaluating the appropriateness, benefits, and risks.

The important point is "to add."

Using medication does not mean one can ignore diet and lifestyle.

If GLP-1 significantly alters appetite, professional support for dietary content may become even more crucial.

The need to broaden the perspective from "weight" to "growth"

The issue to consider from this study is not a simple matter of whether GLP-1 is a good or bad drug.

Severe obesity and type 2 diabetes themselves pose health risks, and some children may not achieve sufficient treatment effects with conventional methods alone.

For such patients, GLP-1 receptor agonists may become an important treatment option.

However, the goal in treating growing children should not be merely to reduce the numbers on the scale.

Is height increasing appropriately?

Are they getting enough protein?

Is there a deficiency in iron or vitamin D?

Is the decrease in appetite not too strong?

Are they not limited to eating only certain foods due to nausea?

Are there any issues with muscle or bone growth?

And is the treatment not causing excessive anxiety about diet or their own body?

Only by combining these multiple perspectives can the true success of pediatric GLP-1 treatment be evaluated.

Moving beyond "success because of weight loss"

GLP-1 receptor agonists have brought significant changes to obesity treatment.

And the stronger the treatment effect, the more important it becomes to support that treatment.

The confirmation of a 16.8% diagnosis related to nutritional deficiencies within a year in this study does not prove that GLP-1 is dangerous.

Rather, it should be considered evidence that "prescribing the medication" alone does not complete the treatment.

Especially for children and adolescents, weight loss and growth must be achieved simultaneously.

If appetite decreases, the treatment is successful.

If weight decreases, the treatment is successful.

Instead of judging by a single number, it is necessary to look at the patient, including nutrition, bones, muscles, growth, and psychological aspects.

As GLP-1 becomes a new option in pediatric obesity treatment, the collaboration of dietitians, pediatricians, obesity treatment specialists, and families becomes more important than ever.

The most important question raised by this study is not a simple yes or no to "should GL